📢 MedInsights is pleased to highlight a significant milestone achieved by our partner, Reventus Pharma, in their drug repositioning strategy for mitochondrial diseases, including MELAS.

💥 Reventus has successfully completed the initial in silico screening phase, identifying a promising shortlist of 27 drug candidates for MELAS from an extensive pool of 65,000 compounds, with additional candidates identified for two other mitochondrial indications.

🔍 This critical first step was executed in close collaboration with MedInsights, leveraging our end to end drug identification and optimization framework, NexusRx, based on network pharmacological approaches. This is one of the many validations of the capabilities of #NEXUSRx as a comprehensive framework for drug repositioning.

💡 A key differentiator of this collaboration was the commitment to full transparency in data and methodology. Reventus was provided comprehensive access to NexusRx and its specialized modules, including those for multi-omics data integration and rare disease modeling. This access fostered a true partnership, enabling seamless data sharing and the incorporation of expert insights throughout the candidate selection process.

🌟 The outcome of this rigorous screening process is a data-driven shortlist of potential therapeutic agents, grounded in robust evidence and disease-specific expertise. This achievement exemplifies the power of strategic insight, facilitated by sophisticated platforms like NexusRx, in accelerating the identification of repositionable candidates for complex rare diseases.

🛣️ This foundational work provides Reventus with a scientifically and strategically sound roadmap for future drug development.

🤝 MedInsights remains committed to empowering our partners with cutting-edge tools and expertise, such as #NexusRx, to address the unmet needs of patients with rare diseases.

Congratulation to all the team members at MedInsights and Reventus Pharma for this amazing collaborative effort.

Dimitrije M., Nathalie Barreto Lefebvre, Manish Sarkar, Soham Saha, Ph.D., Pierre-Axel Monternier.

#RareDisease #DrugRepositioning #MitochondrialDisease #MELAS #PrecisionMedicine #NexusRx #MedInsights #Reventus #Innovation #NEXUSRx

MedInsights is proud to be present in the INTERNATIONAL DRUG REPURPOSING CONFERENCE #idr25 conference titled, "Medicines Reimagined: Unlocking the Potential of Existing Drugs for Patient Benefit."
The key highlights of the #IDR25 held conference in Amsterdam 🏙️ are:

💊 🚀 Unlocking the Potential of Existing Medicines: The Power of #Drug #Repurposing 🚀
In a rapidly innovating healthcare and digital world, the strategic approach of drug repurposing is gaining momentum. It's not just about finding new and innovative drugs; it's about accelerating the access to treatments, particularly for diseases of high unmet needs.

💡 AI: The Intelligent Partner in Repurposing
#Artificial #Intelligence (AI) is proving to be a game-changer in this field. Its ability to identify novel repurposing opportunities and assess drug effects with unprecedented speed and accuracy is truly #transformative.

🤝 Collaboration: The #Cornerstone of #Success
Drug repurposing isn't a solo endeavor; it's a team sport involving multitudes of actors and stakeholders. Transitioning from the basic research to patient access requires robust partnerships and the active involvement of key stakeholders. Real-life examples and initiatives demonstrate the power of working together to bridge this critical gap. #Collaboration across sectors and borders, with meaningful patient input, is vital for advancing repurposing efforts for wider communities and the diseases of high unmet needs.

🛣️ Navigating Pathways and Pioneering Trial Designs
Understanding the #current #pathways and #initiatives that facilitate #patient #access to repurposed treatments is crucial. Furthermore, embracing novel and innovative trial designs is essential, especially when conducting research in historically challenging populations like those with rare diseases. Innovative financing mechanisms and a mixed economy approach are key to ensuring the long-term viability of repurposing initiatives.

❤️ Putting Patients at the Heart of it all!
Ultimately, the success of drug repurposing hinges on delivering meaningful #outcomes for #patients. Selecting endpoints that are relevant to the patient community significantly impacts their experience and overall outcomes.

It was a great opportunity to connect with amazing leaders and share interesting insights and thoughts. Thanks to Oliver Weyand, Stefan Gold, Megan Golden, Anton Ussi, Anna Cichońska, Barber Tinselboer, Alicia Soler Cantón, Jeanie Kim, Jan Baumbach and Harald H.H.W. Schmidt 🕸️💊for sharing your thoughts and learnings with the aim to improve access to drugs for patients with us.

Midas Pharma, Charité - Universitätsmedizin Berlin, EATRIS, Harmonic Discovery, SATB2 Europe, University of Hamburg, Dompé, ERDERA, REPO4EU, Chan Zuckerberg Initiative REMEDi4ALL
Manish Sarkar
Soham Saha, Ph.D.
#idr25 #drugrepurposing #rarediseases #oncology #unmetneed #patientscentricity #amsterdam #felixmeritis #remedi4all

🚀 Addressing a major hurdle in rare disease translational science!

🐁 Identifying effective animal models has long been a bottleneck due to biases in traditional methods and the difficulty of cross-analyzing with human disease manifestations.

📢 We are thrilled to announce our preprint entitled "A novel computational framework to identify translational potential of genetic mouse models in rare genetic obesity" which introduces the #OptiMouse module within our integrated drug repurposing framework #NEXUSRx.

💡 This case study demonstrates the capability of #OptiMouse by simultaneously analyzing data from 106 mouse models of genetic obesity and over 600 different phenotypes. The analysis revealed unexpected and hidden connections between obesity and 16 other diseases, showcasing the framework's potential to make more informed, disease-specific decisions in disease model selection.

🔗 Here is the preprint link:
https://lnkd.in/ewHHVif5

💐 Huge congratulations to Nathalie Barreto Lefebvre, Aleksandra Polosukhina, Ph.D., Catarina Barata, Michel Leibovici, Pamela Le Quéré, Marcelo Paez-Pereda, Ph.D., Soham Saha, Ph.D. and franck oury on this significant advancement that promises to modernize rare disease research and pave the way for more effective therapies. This study is a part of the Masters thesis work performed by Nathalie Barreto Lefebvre at Instituto Superior Técnico.

🤝 MedInsights, INEM - Institut Necker Enfants Malades, Instituto Superior Técnico
#raredisease #translationalscience #animalmodels #computationalbiology #OptiMouse #NEXUSRx #obesityresearch #industryacademiacollaboration

💊 The International Drug Repurposing Conference (iDR25) will take place in Amsterdam, Netherlands from 7-8 May, 2025 and MedInsights is thrilled to be participating!
🔍 iDR25 is set to explore a spectrum of pivotal areas, from the transformative potential of cutting-edge AI approaches in drug discovery 🤖 to the development of innovative business models for successful drug repurposing 💼 and the crucial task of navigating regulatory pathways for accelerated market access 📜.
🏥 We are looking forward to engaging with key opinion leaders from research, patient communities, clinicians, policymakers, funders, regulators, and the private sector.
iDR25 will be a fantastic opportunity to:
➡️ Connect with experts in the field of drug repurposing🤝
➡️ Discuss the latest advancements and challenges in this field 🗣️
➡️ Collaborate on innovative solutions for increased patient access 💡

Join Soham Saha, Ph.D. and Manish Sarkar, at iDR25 to learn about our innovative drug repurposing strategies targeting diseases with critical unmet needs.
Don't hesitate to check out our website: https://lnkd.in/dMn_3ywZ
REMEDi4ALL
#iDR25 #DrugRepurposing #AI #Innovation #Healthcare #Pharmaceuticals #SystemsMedicine #Research #Collaboration #MedInsights

🖋️ Over two centuries ago, Stendhal (1783 — 1842) articulated a truth that remains profoundly relevant today "The admission of women to perfect equality would be the surest mark of civilization, and it would double the intellectual strength of the human race and its chances of happiness."

🔍 This timeless insight, penned centuries ago, resonates just as strongly today. As we mark International Women's Day, MedInsights acknowledges the critical need to accelerate progress towards gender parity.

👪 The World Economic Forum's data indicates that, at the current rate, achieving full gender parity will take until 2158. That's a staggering 134 years, or roughly five generations. This delay represents a significant loss of potential—a loss of innovation, leadership, and diverse perspectives that are essential for driving progress in development and beyond.

⚡ At MedInsights, we recognize that gender equality is not just a moral imperative, but a strategic one. Diverse teams lead to better problem-solving, improved framework design and execution, and more robust healthcare solutions. We are committed to fostering an inclusive environment where all kinds and forms of contributions are valued and amplified.
Nathalie Barreto Lefebvre Dimitrije M. Manish Sarkar Soham Saha, Ph.D.
#JournéeDesDroitsDesFemmes #InternationalWomensDay #IWD2025 #AccelerateAction #GenderEquality #HealthcareLeadership #MedInsights #DiversityAndInclusion #WomensHealth